ir.titanpharm.comInvestor Relations :: Titan Pharmaceuticals, Inc. (TTNP)
ir.titanpharm.com Profile
ir.titanpharm.com
Maindomain:titanpharm.com
Title:Investor Relations :: Titan Pharmaceuticals, Inc. (TTNP)
Description:For more information about Titan please visit wwwtitanpharmcom Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934
Discover ir.titanpharm.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
ir.titanpharm.com Information
Website / Domain: |
ir.titanpharm.com |
HomePage size: | 45.219 KB |
Page Load Time: | 0.233524 Seconds |
Website IP Address: |
13.56.73.31 |
Isp Server: |
Xerox Corporation |
ir.titanpharm.com Ip Information
Ip Country: |
United States |
City Name: |
Norwalk |
Latitude: |
41.125736236572 |
Longitude: |
-73.44017791748 |
ir.titanpharm.com Keywords accounting
ir.titanpharm.com Httpheader
Date: Mon, 27 Jul 2020 16:49:43 GMT |
Server: Apache |
Vary: Accept-Encoding |
Content-Encoding: gzip |
Content-Length: 7631 |
Keep-Alive: timeout=5, max=100 |
Connection: Keep-Alive |
Content-Type: text/html; charset=UTF-8 |
ir.titanpharm.com Meta Info
charset="utf-8"/ |
content="Titan Pharmaceuticals, Inc." property="og:site_name"/ |
content="Investor Relations" property="og:title"/ |
content="website" property="og:type"/ |
content="https://d1io3yog0oux5.cloudfront.net/_200bc761fc2bbafa0300c9c44b9ad1c3/titanpharm/logo.png" property="og:image"/ |
content="https://ir.titanpharm.com" property="og:url"/ |
content="initial-scale=1.0, width=device-width" name="viewport"/ |
content="#ffffff" name="msapplication-TileColor"/ |
content="https://d1io3yog0oux5.cloudfront.net/_200bc761fc2bbafa0300c9c44b9ad1c3/titanpharm/files/images/mstile-144x144.png" name="msapplication-TileImage"/ |
content="#ffffff" name="theme-color"/ |
13.56.73.31 Domains
ir.titanpharm.com Similar Website
Domain |
WebSite Title |
ir.titanpharm.com | Investor Relations :: Titan Pharmaceuticals, Inc. (TTNP) |
ir.supernus.com | Investor Relations - Supernus Pharmaceuticals |
ir.progenics.com | Investor Relations | Progenics Pharmaceuticals, Inc. |
investors.vrtx.com | Investor Relations | Vertex Pharmaceuticals |
investor.enzon.com | Investor Relations | Enzon Pharmaceuticals |
investors.amneal.com | Amneal Pharmaceuticals Inc - Investor Relations |
investor.regeneron.com | Investor Relations | Regeneron Pharmaceuticals Inc. |
newsroom.regeneron.com | Investor Relations | Regeneron Pharmaceuticals Inc. |
investors.aeriepharma.com | Investor Relations | Aerie Pharmaceuticals, Inc |
ir.alexion.com | Investor Relations | Alexion Pharmaceuticals, Inc. |
investor.eagleus.com | Eagle Pharmaceuticals Investor Center | |
investor.sppirx.com | Investor Relations - Spectrum Pharmaceuticals, Inc. |
investor.ligand.com | Investor Summary :: Ligand Pharmaceuticals Incorporated (LGND) |
zuchepharma.trustpass.alibaba.com | ZUCHE PHARMACEUTICALS PRIVATE LIMITED - Pharmaceuticals,Medical Devices |
aeriepharma.com | Aerie Pharmaceuticals | Leading Ophthalmic Pharmaceuticals |
ir.titanpharm.com Traffic Sources Chart
ir.titanpharm.com Alexa Rank History Chart
ir.titanpharm.com Html To Plain Text
Navigate Titan Pharmaceuticals, Inc. Home About Overview Who We Are Strategic Alliances IP Portfolio Management Team Board of Directors Careers Technology Pipeline Overview Probuphine Ropinirole Implant T3 Implant News Overview Press Releases Events Presentations In the News Publications Posters Media Resources Investors Investor Relations Overview News / Events Press Releases IR Calendar Email Alerts Company Info Company Information Profile Presentations Management Team Contacts FAQ Financial Info Financials Financial Results Stock Data Quote Charts Historical Data SEC Filings All SEC Filings Annual Reports Quarterly Reports Section 16 Filings Governance Board of Directors Board Committees Governance Documents Contact Search Investor Relations Titan is advancing the treatment of select chronic diseases by developing therapeutics based on its proprietary long-term, continuous drug delivery platform, ProNeura. Download Latest Presentation Proneura Titan's proprietary long-term, drug delivery platform provides continuous drug release and non-fluctuating medication levels over a period of three months to a year depending on drug characteristics. Probuphine The U.S. Food and Drug Administration approved Probuphine for the long-term maintenance treatment of opioid dependence on May 26, 2016. Ropinirole The potential to deliver coninuous, non-fluctuating levels of dopamine agonists and provide CDS for 3 months and potentially longer from a single treatment. Home Investors Overview Overview Investors Navigate Investors Overview News / Events Company Information Financial Information Stock Data SEC Filings Corporate Governance Email Alerts Tear Sheet Contacts RSS News Feed Latest News July 8, 2020 Titan Pharmaceuticals Urges Stockholders to Vote "FOR" Proposal to Amend Its Certificate of Incorporation Read Press Release Upcoming Event August 12, 2020 • 9:00AM PDT Special Meeting of Stockholders IR Calendar Latest Financial Results Q1 2020 Quarterly Results March 31, 2020 PDF HTML Release PDF HTML 10-Q Filing HTML Financials ZIP XLS HTML XBRL Stock Quote Titan Pharmaceuticals, Inc. Nasdaq: TTNP Volume Day Low/High 52 Week Low/High Company Overview Titan is a specialty pharmaceuticals company that develops therapeutics for select chronic diseases utilizing its innovative, long-term, continuous drug delivery platform, ProNeura. The company's lead product is Probuphine, a six-month buprenorphine implant for the maintenance treatment of opioid addiction. On May 26, 2016, the U.S. Food and Drug Administration approved Probuphine for the long-term maintenance treatment of opioid dependence in stable patients receiving a low to moderate daily dose of oral buprenorphine therapy. Probuphine is the first marketed product to provide maintenance treatment of opioid addiction continuously for six months following a single administration procedure. View Presentation Officers & Directors Executive Leadership Board of Directors Marc Rubin, MD Executive Chairman Dr. Rubin has served as Titan's Executive Chairman of the Board of Directors since 2009, after previously holding the position of CEO. Prior to joining Titan, Dr. Rubin was Head of Global Research and Development for Bayer Schering Pharma,… View Full Bio Sunil Bhonsle, MBA President and CEO Sunil Bhonsle has served as Titan's President since 2009, after previously holding the positions of Executive Vice President and Chief Operating Officer. Prior to joining Titan, Mr. Bhonsle served for 20 years at Bayer Corp., where he was… View Full Bio Kate DeVarney, Ph.D. Executive Vice President and Chief Scientific Officer Dr. DeVarney joined Titan in January 2007 to lead the clinical development and medical affairs group and currently serves as Titan's Executive Vice President and Chief Development Officer. Before joining Titan, she was a Senior Director… View Full Bio Marc Rubin, MD Executive Chairman Dr. Rubin has served as Titan's Executive Chairman of the Board of Directors since 2009, after previously holding the position of CEO. Prior to joining Titan, Dr. Rubin was Head of Global Research and Development for Bayer Schering Pharma,… View Full Bio Sunil Bhonsle, MBA President and CEO Sunil Bhonsle has served as Titan's President since 2009, after previously holding the positions of Executive Vice President and Chief Operating Officer. Prior to joining Titan, Mr. Bhonsle served for 20 years at Bayer Corp., where he was… View Full Bio Kate DeVarney, Ph.D. Executive Vice President and Chief Scientific Officer Dr. DeVarney joined Titan in January 2007 to lead the clinical development and medical affairs group and currently serves as Titan's Executive Vice President and Chief Development Officer. Before joining Titan, she was a Senior Director… View Full Bio Joseph A. Akers Audit Committee Mr. Akers has served as president of Bayer's hematology/cardiology business, where he oversaw the core of Bayer's specialty pharmaceuticals development, with significant products in hematology and specialty cardiology. Mr. Akers also… View Full Bio M. David MacFarlane, PhD Audit Committee; Corporate Governance and Nominating Committee Dr. MacFarlane has been a Director of Titan Pharmaceuticals since May 2002. Dr. MacFarlane served as Vice President and Responsible Head of Regulatory Affairs of Genentech, Inc. from 1989 until his retirement in August 1999. Prior to… View Full Bio James R. McNab, Jr. Corporate Governance and Nominating Committee Mr. McNab, an entrepreneur experienced in building and growing companies, is co-founder and chairman of Curis, a publicly traded oncology company that partnered with Roche to develop and commercialize a first-in-class hedgehog inhibitor… View Full Bio Scott Smith Director In his current role as president of global inflammation and immunology, Mr. Smith leads a team of over 1,300 people and is responsible for the inflammation and immunology portfolio, including all global commercial, clinical development,… View Full Bio Federico Seghi Recli Board Observer (Molteni) An executive with over 24 years of leadership experience within the pharmaceutical industry, Mr. Seghi Recli has served in a number of executive positions with L. Molteni & C. dei F. lli Alitti Società di Esercizio S.p.A., which, in… View Full Bio © 2020 Titan Pharmaceuticals, Inc. All Rights Reserved. Privacy Policy Disclaimer Sitemap...
ir.titanpharm.com Whois
"domain_name": "TITANPHARM.COM",
"registrar": "GoDaddy.com, LLC",
"whois_server": "whois.godaddy.com",
"referral_url": null,
"updated_date": [
"2017-12-08 03:56:56",
"2017-12-08 03:56:55"
],
"creation_date": "1997-02-14 05:00:00",
"expiration_date": "2027-02-15 05:00:00",
"name_servers": [
"NS07.DOMAINCONTROL.COM",
"NS08.DOMAINCONTROL.COM"
],
"status": [
"clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited",
"clientRenewProhibited https://icann.org/epp#clientRenewProhibited",
"clientTransferProhibited https://icann.org/epp#clientTransferProhibited",
"clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited",
"clientTransferProhibited http://www.icann.org/epp#clientTransferProhibited",
"clientUpdateProhibited http://www.icann.org/epp#clientUpdateProhibited",
"clientRenewProhibited http://www.icann.org/epp#clientRenewProhibited",
"clientDeleteProhibited http://www.icann.org/epp#clientDeleteProhibited"
],
"emails": "abuse@godaddy.com",
"dnssec": "unsigned",
"name": null,
"org": "Titan Pharmaceuticals, Inc.",
"address": null,
"city": null,
"state": "California",
"zipcode": null,
"country": "US"